Post-surgical outcome and prognostic factors in canine malignant melanomas of the haired skin: 87 cases (2003-2015).

The medical records of 87 dogs treated with surgery for cutaneous malignant melanoma (CMM) of the haired skin were retrospectively reviewed for overall survival time (OST), progression-free survival time (PFS), and prognostic factors. The post-surgery median PFS and median OST were 1282 days and 1363 days, respectively. The post-surgery metastatic rate was 21.

Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).

Objective: To determine clinical activity and toxic effects of lomustine when used to treat cats with mast cell tumors (MCTs).

Design: Retrospective case series.

Animals: 38 cats with measurable, histologically or cytologically confirmed MCTs treated with lomustine at a dosage > or = 50 mg/m(2).

Clinical and immunohistochemical differentiation of gastrointestinal stromal tumors from leiomyosarcomas in dogs: 42 cases (1990-2003).

Objective: To reexamine (via immunohistochemical techniques) canine tissue samples that had been previously classified as gastrointestinal leiomyosarcomas (GILMSs), identify and differentiate gastrointestinal stromal tumors (GISTs) from GILMSs, and compare the biological behavior and clinical course of GISTs and GILMSs in dogs.

Design: Retrospective case series.

Animals: 42 dogs.

A prospective investigation of the prevalence and prognostic significance of weight loss and changes in body condition in feline cancer patients.

The objectives of this study were to prospectively identify and characterize weight loss and changes in body condition in feline cancer patients and to investigate the prognostic significance of these findings. Fifty-seven cats with neoplasia were evaluated. Body condition was assessed with a nine-point scoring system (BCS) and multiple sites were assessed for muscle and fat mass using four-point scoring systems.

Liposarcomas in dogs: 56 cases (1989-2000).

Objective: To determine the biological behavior of liposarcomas in dogs and identify clinical signs, the effect of treatment on survival time, and potential prognostic factors.

Design: Retrospective study.

Animals: 56 dogs with histologically confirmed liposarcoma.

Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma.

The purpose of this study was to evaluate the efficacy and toxicity of a single-agent, dose-intensified doxorubicin protocol in canine hemangiosarcoma (HSA). Canine HSA is a highly malignant tumor, and most affected dogs die within 6 months of diagnosis. Doxorubicin is the most, and possibly the only, effective chemotherapeutic drug for this malignancy, but it provides only moderate improvement in survival.